<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abnormalities of the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile partly explain the atherogenic tendency of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> but the picture is unclear in thrombotic <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>Herein we compare the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>), <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>), total cholesterol (<z:chebi fb="0" ids="29327">CHO</z:chebi>), <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A (ApoA-I), <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (ApoB), <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (TRY)), anti-<z:chebi fb="1" ids="6495">lipoprotein</z:chebi> antibodies, beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I complexed to oxidized <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (oxLDL-ss(2)GPI) and C-reactive protein (CRP) from thrombotic PAPS (n = 34), thrombotic patients with inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (IT; n = 36), subjects persistently positive for <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL, n = 18) with no underlying autoimmune or non-<z:hpo ids='HP_0002960'>autoimmune disorders</z:hpo> and healthy controls (n = 28) and determined the reciprocal effects of anti-<z:chebi fb="1" ids="6495">lipoprotein</z:chebi> antibodies, the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, oxLDL-ss(2)GPI and CRP </plain></SENT>
<SENT sid="2" pm="."><plain>Average concentrations of <z:chebi fb="17" ids="39025">HDL</z:chebi> (p &lt; 0.0001), <z:chebi fb="15" ids="39026">LDL</z:chebi> (p &lt; 0.0001), <z:chebi fb="0" ids="29327">CHO</z:chebi> (p = 0.0002), ApoA-I (p = 0.002) were lower in PAPS whereas average TRY was higher (p = 0.01) than other groups </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, the aPL and PAPS group showed higher levels of IgG anti-<z:chebi fb="17" ids="39025">HDL</z:chebi> (p = 0.01) and IgG anti-ApoA-I (p &lt; 0.0001) whereas the PAPS group showed greater average oxLDL-ss(2)GPI (p = 0.001) and CRP (p = 0.003) </plain></SENT>
<SENT sid="4" pm="."><plain>Within the PAPS group, IgG anti-<z:chebi fb="17" ids="39025">HDL</z:chebi> correlated negatively to <z:chebi fb="17" ids="39025">HDL</z:chebi> (p = 0.004) and was an independent predictor of oxLDL-ss2GPI (p = 0.009) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> and ApoA-I correlated negatively with CRP (p = 0.001 and p = 0.007, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>IgG anti-<z:chebi fb="17" ids="39025">HDL</z:chebi> may hamper the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory effect of <z:chebi fb="17" ids="39025">HDL</z:chebi> favoring low-grade <z:mp ids='MP_0001845'>inflammation</z:mp> and enhanced oxidation in thrombotic PAPS </plain></SENT>
</text></document>